Exonate

Exonate is a clinical-stage biotech pioneering a first-in-class, topical therapy for retinal vascular diseases. Its lead asset, EXN407, is a small molecule SRPK1 inhibitor designed as an eye drop to treat diabetic retinopathy and diabetic macular oedema by influencing VEGF alternative splicing. Having completed a Phase Ib/IIa trial, the company is preparing for a Phase IIb trial in 2026, positioning itself to address a significant unmet need for non-invasive treatments. Founded in 2013 as a university spin-out, Exonate is a private, well-funded company with strong scientific foundations and advisory support.

Proprietary small molecule inhibitors of SRPK1, a kinase that regulates VEGF alternative splicing. The platform aims to shift VEGF production from pro-angiogenic to anti-angiogenic isoforms, enabling development of topical eye drop therapies for retinal diseases.

Exonate competes in the retinal disease market dominated by anti-VEGF injectables (e.g., Roche/Genentech, Regeneron, Bayer). Its primary differentiation is the topical route of administration. Competition also comes from companies developing longer-acting injections, implants, and gene therapies to reduce treatment burden. Its novel splicing mechanism is a unique scientific approach.